Tucatinib
HER2-expressing Cancers
Jazz PharmaceuticalsSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the HER2-expressing Cancers cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Capecitabine Jazz Pharmaceuticals | Phase 1 | CC |
Eloxatin Jazz Pharmaceuticals | Phase 1 | CC |
Zanidatamab Jazz Pharmaceuticals | Phase 1 | CC |
Vinorelbine Jazz Pharmaceuticals | Phase 1 | CC |
ZANIDATAMAB ZOVODOTIN Zymeworks BC Inc. | Phase 1 | CC |
Same molecule, other indications
Tucatinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →